Skip to content

Diet, ExerCIse and carDiovascular hEalth (DECIDE) - Salt Reduction Strategies for the Elderly in Nursing Homes in China

Diet, Exercise and Cardiovascular Health - Effect of Salt Substitute and Stepwise Salt Supply Control in Reducing Blood Pressure in the Elderly in Nursing Homes in China: a Factorial Cluster-randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03290716
Acronym
DECIDE-Salt
Enrollment
1612
Registered
2017-09-25
Start date
2017-09-25
Completion date
2021-05-11
Last updated
2021-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Pressure

Brief summary

The DECIDE - Salt in Elderly (Diet, ExerCIse and carDiovascular hEalth - Salt Reduction Strategies for the Elderly in Nursing Homes in China) is to evaluate the effects, safety and cost-effectiveness of salt substitution (SS) and stepwise salt supply control (SSSC) in reducing blood pressure in Chinese elderly in nursing homes. The study will recruit over 960 old people from 48 nursing homes in northern China. The 48 nursing homes will be randomised into the following 4 groups. 1. salt substitute (SS) and stepwise salt supply control (SSSC); 2. SS only; 3. SSSC only; and 4. no SS and no SSSC (control). The intervention will last over 2 years. The randomization will be conducted centrally after the baseline survey completed. Primary outcome will be the change in systolic blood pressure. The secondary outcomes include: the changes in diastolic blood pressure, 24hr urinary sodium, potassium and microalbumin, and incidence of hyperkalemia, hypokalemia, hyponatremia, cardiovascular events, and all causes death, and incremental cost-effectiveness ratio.

Detailed description

The DECIDE - Salt in Elderly (Diet, ExerCIse and carDiovascular hEalth - Salt Reduction Strategies for the Elderly in Nursing Homes in China) is a study in the DECIDE project, which includes five studies. The others are DECIDE - Diet, DECIDE - Exercise, DECIDE - Obesity in Children, and DECIDE - Smart Living. The DECIDE - Salt in Elderly study is to evaluate the effects, safety and cost-effectiveness of salt substitution (SS) and kitchen-based stepwise salt supply control (SSSC) in reducing blood pressure in Chinese elderly in nursing homes. Specifically, the study aims include: 1. to test if a stepwise salt supply control strategy could significantly reduce systolic blood pressure among elderly living in nursing homes; 2. to test if replacing regular salt with the market available salt substitute could significantly reduce systolic blood pressure among elderly living in nursing homes; and 3. to test if the joint effect of the two strategies is larger than that from one of each. The corresponding null hypotheses that will be tested are: 1. the mean change from the baseline in systolic blood pressure of elderly residents in nursing homes that are supplied with SS is equal to the mean change from the baseline in systolic blood pressure of elderly residents in nursing homes that are supplied with regular salt; 2. the mean change from the baseline in systolic blood pressure of elderly residents in nursing homes that apply SSSC is equal to the mean change from the baseline in systolic blood pressure of elderly residents in nursing homes that do not apply SSSC; 3. There is no interaction between the two interventions above. The study will recruit over 960 old people from 48 nursing homes in northern China, where the mean salt intake is generally higher than 12 g/day. A 2x2 factorial cluster-randomized trial will be used to test two independent salt reduction strategies: 1) using salt substitute to replace the regular salt in the kitchen of nursing homes; and 2) training the nursing manager to control/reduce, step by step, the amount of salt supplied to the kitchen of nursing homes. The 48 nursing homes will be randomized to the following 4 groups. 1. salt substitute (SS) and stepwise salt supply control (SSSC); 2. SS only; 3. SSSC only; and 4. no SS and no SSSC (control). A brief health education on salt and health will be applied to all four groups. The salt substitute (NaCl 62.5% and KCl 25%) will be centrally provided. And the Train-the-trainers model will be used to train the nursing home managers how to implement the SSSC. The intervention will last over 2 years. The baseline examination including three blood pressure measurements and one 24-hr urine collection will be conducted for all participants. Fasting blood samples will be drawn for measurement of serum potassium and detect hyperkalemia, hypokalemia, hyponatremia and renal dysfunction. The randomization will be conducted centrally by the study coordinating center at Peking University Clinical Research Institute, after the baseline survey completed. All participants will be followed up for blood pressure measurements at 6, 12, 18 and 24 months, for serum potassium at 12 and 24 months, and for 24-hr urine collection at 24 months. Study outcomes: Primary outcome: The change in systolic blood pressure from baseline to follow-up. Secondary outcomes: The incidence of hyponatremia, hyperkalemia, hypokalemia and renal dysfunction from the baseline to 24 months. The change in 24-hr urinary sodium, potassium and microalbumin from the baseline to 24 months. The change in diastolic blood pressure from baseline to follow-up. The incremental cost-effectiveness ratio (ICER). The incidence of cardiovascular events and all causes death during follow up. Power analysis: On the assumptions of a 20% dropout rate, an intraclass correlation of 0.02, the number of clusters of 48 and at least 20 elderly people in each nursing home, and an α value of 0.05, the study to detect a mean 3.0 mmHg reduction in systolic blood pressure (SD, 18 mm Hg) between the intervention groups would have a power of 0.81. To detect a 4.0 mmHg reduction in systolic blood pressure (SD, 18 mm Hg), the power of the same sample size would be 0.96. Statistical analysis: Linear models adjusted for clustering based on participants with available measures were used to assess continuous outcomes. Frailty survival models that account for clustering based upon all randomised participants were used for analysis of the effects on cardiovascular and mortality outcomes. Generalized linear mixed model were used for analysis of effects on hyperkalemia, hypokalemia, hyponatremia and renal dysfunction.. Ethical considerations: The study will be submitted to and approved by the Peking University IRB, which has the full accreditation from AAHRRP. The study salt substitute is the product available on Chinese market and has been approved manufactured according to the product standards issued by the ministry of health. The SSSC approach will take every step for 3 months and the biggest step of salt reduction will be just 10% of the original amount of use. And the study will ensure an interview will be conducted to collect the feedback before every next step will take place. The SSSC intervention will stop at any time that elderly people feel unlike the foods.

Interventions

OTHERSS

Replace regular salt with market available potassium-enriched salt substitute in kitchens of nursing homes.

OTHERSSSC

A stepwise approach to reduce salt used in the kitchen of nursing homes by controlling the supply of salt.

Sponsors

Changzhi Medical College
CollaboratorOTHER
Xi'an Jiaotong University
CollaboratorOTHER
Hohhot Center for Disease Control and Prevention
CollaboratorUNKNOWN
Yangcheng Ophthalmology Hospital
CollaboratorUNKNOWN
Peking University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
55 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Eligibility of nursing homes: * To be eligible, the nursing home must has not participated in any salt reduction or other intervention trials, has at least 20 residents and has agreed to participate in the study. Eligibility of individual elderly: Inclusion Criteria: * Living in the nursing home permanently or expectedly for the coming two years * Age less than 55 years. * Life expectancy over six months. * Provide written informed content.

Exclusion criteria

* Clinically confirmed hyperkalemia

Design outcomes

Primary

MeasureTime frameDescription
The change in systolic blood pressure from baseline to follow-upbaseline、6 month、12 month、18 month and 24-month follow-upmmHg

Secondary

MeasureTime frameDescription
The incidence of hypokalemiathroughout 24 months of follow-upA new case of hypokalemia is defined as having serum potassium \<3.5 mmol/L at either month 12 or 24 among participants with normal serum potassium at the baseline, regardless of clinical manifestations.
The change in 24-hour urinary sodium and potassiumbaseline and 24-month follow-upmmol/d
The change in 24-hour urinary microalbuminbaseline and 24-month follow-upmg/day
The change in diastolic blood pressure from baseline to follow-upbaseline、6 month、12 month、18 month and 24-month follow-upmmHg
The incidence of hyperkalemiathroughout 24 months of follow-upA new case of hyperkalemia is defined as having serum potassium \>5.5 mmol/L at either month 12 or 24 among participants with normal serum potassium at the baseline, regardless of clinical manifestations.
Cardiovascular eventsthroughout 24 months of follow-upfatal and nonfatal stroke, fatal and nonfatal myocardial infarction, hospitalization for congestive heart failure
Deaththroughout 24 months of follow-upall causes death
The incidence of hyponatremiathroughout 24 months of follow-upA new case of hyponatremia is defined as having serum sodium \<135 mmol/L at either 12 or 24 months with normal serum sodium at the baseline, regardless of clinical manifestations.
The incidence of renal dysfunctionthroughout 24 months of follow-upA new case of renal dysfunction is defined as having eGFR \<60 at either 12 or 24 months with normal eGFR at the baseline, regardless of clinical manifestations.
ICERthroughout 24 months of follow-upIncremental cost-effectiveness ratio, defined by the difference in the cost for every unit of gain in the pertained effectiveness outcome

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026